135 related articles for article (PubMed ID: 28035779)
1. Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
Morihara R; Yamashita T; Kono S; Shang J; Nakano Y; Sato K; Hishikawa N; Ohta Y; Heitmeier S; Perzborn E; Abe K
J Neurosci Res; 2017 Sep; 95(9):1818-1828. PubMed ID: 28035779
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
Kono S; Yamashita T; Deguchi K; Omote Y; Yunoki T; Sato K; Kurata T; Hishikawa N; Abe K
Stroke; 2014 Aug; 45(8):2404-10. PubMed ID: 24984746
[TBL] [Abstract][Full Text] [Related]
3. Effects of Pretreatment with Warfarin or Rivaroxaban on Neurovascular Unit Dissociation after Tissue Plasminogen Activator Thrombolysis in Ischemic Rat Brain.
Shang J; Yamashita T; Kono S; Morihara R; Nakano Y; Fukui Y; Li X; Hishikawa N; Ohta Y; Abe K
J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):1997-2003. PubMed ID: 27230587
[TBL] [Abstract][Full Text] [Related]
4. Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Kono S; Deguchi K; Omote Y; Yunoki T; Yamashita T; Kurata T; Ikeda Y; Abe K
J Neurosci Res; 2014 Jan; 92(1):46-53. PubMed ID: 24265137
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Ploen R; Sun L; Zhou W; Heitmeier S; Zorn M; Jenetzky E; Veltkamp R
J Cereb Blood Flow Metab; 2014 Mar; 34(3):495-501. PubMed ID: 24346690
[TBL] [Abstract][Full Text] [Related]
6. In Models of Intracerebral Hemorrhage, Rivaroxaban is Superior to Warfarin to Limit Blood Brain Barrier Disruption and Hematoma Expansion.
Sawada S; Ono Y; Egashira Y; Takagi T; Tsuruma K; Shimazawa M; Iwama T; Hara H
Curr Neurovasc Res; 2017; 14(2):96-103. PubMed ID: 27993122
[TBL] [Abstract][Full Text] [Related]
7. Thrombolysis with rt-PA under Rivaroxaban Anticoagulation in a Hypertensive Rat Model of Intraluminal Middle Cerebral Artery Occlusion.
Izuma H; Oka F; Ishihara H; Inoue T; Suehiro E; Nomura S; Suzuki M
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2761-2767. PubMed ID: 30056000
[TBL] [Abstract][Full Text] [Related]
8. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
[TBL] [Abstract][Full Text] [Related]
9. Rapid reversal of anticoagulation prevents excessive secondary hemorrhage after thrombolysis in a thromboembolic model in rats.
Sun L; Zhou W; Ploen R; Heiland S; Zorn M; Veltkamp R
Stroke; 2011 Dec; 42(12):3524-9. PubMed ID: 21960573
[TBL] [Abstract][Full Text] [Related]
10. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin.
Mazya MV; Lees KR; Markus R; Roine RO; Seet RC; Wahlgren N; Ahmed N;
Ann Neurol; 2013 Aug; 74(2):266-74. PubMed ID: 23744571
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway.
Puech C; Delavenne X; He Z; Forest V; Mismetti P; Perek N
Brain Res; 2019 Sep; 1719():57-63. PubMed ID: 31121158
[TBL] [Abstract][Full Text] [Related]
12. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Muhammad S; Planz O; Schwaninger M
Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
[TBL] [Abstract][Full Text] [Related]
13. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
14. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
15. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Dittmeier M; Kraft P; Schuhmann MK; Fluri F; Kleinschnitz C
Thromb Haemost; 2016 Apr; 115(4):835-43. PubMed ID: 26489881
[TBL] [Abstract][Full Text] [Related]
17. Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats.
Copin JC; Gasche Y
Brain Res; 2008 Dec; 1243():161-6. PubMed ID: 18835259
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
19. Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Saguchi T; Onoue H; Urashima M; Ishibashi T; Abe T; Furuhata H
Stroke; 2008 Mar; 39(3):1007-11. PubMed ID: 18239172
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
